What is Prostatype?
For men with localized prostate cancer, choosing the right management is critical for peace of mind and optimal long-term outcomes.
The Prostatype® Genomic Classifier gives confidence that Active Surveillance is the correct decision.
What is Prostatype?
For men with localized prostate cancer, choosing the right therapy is critical for peace of mind and optimal long-term outcomes.
The Prostatype® Genomic Classifier helps guide Active Surveillance decisions.
The Prostatype Genomic ClassifierTM or PGCTM is a new-generation prognostic test for men diagnosed with localized prostate cancer who are considering active surveillance.
Stemming from more than 15 years of research by internationally recognized scientists at the Karolinska Institute in Stockholm Sweden, Prostatype measures the expression profiles of three cancer stem cell genes associated with prostate cancer aggressiveness to support treatment decisions.
The Prostatype Genomic Classifier is a noninvasive test performed on tumor tissue from the patient’s existing prostate biopsy, eliminating the need for another invasive procedure. Importantly, it is the only test developed on biopsy tissue from untreated patients, to accurately determine a patient’s risk for having unidentified aggressive cancer that the biopsy missed. This is called adverse pathology and would be discovered if the patient had a radical prostatectomy. The Prostatype GC also predicts a man’s 5- and 10-year risk for metastasis, and his 5- and 10-year risk of death from prostate cancer if he chooses Active Surveillance.
The Prostatype Genomic Classifier has been clinically validated in numerous peer-reviewed studies demonstrating improved patient risk stratification. By combining the patient’s gene expression results with clinical parameters such as PSA, Gleason Score, and Tumor Stage, the Prostatype test provides an objective calculation of the patient’s personalized risk for aggressive disease.
Prostatype helps identify men at increased risk for adverse pathology, metastases, and prostate cancer-specific mortality, who would benefit from early intervention and curative treatment. On the other hand, the test also helps identify men who are at substantially lower risk for these events and who may confidently choose active surveillance, thereby avoiding unnecessary surgery or radiation treatment and the associated side effects.
Choosing active surveillance, and foregoing treatment, is a difficult decision – Prostatype provides patients with personalized insights to support their decision with greater peace of mind.